Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …

Acquired hemophilia A is a bleeding disorder caused by antibodies to factor VIII (FVIII).
These antibodies—called inhibitors—interfere with normal hemostasis, leading to potentially …

Acquired hemophilia A and acquired von Willebrand syndrome are rare, but life-threatening
bleeding disorders that require prompt diagnosis and treatment by hematologists. Acquired …

We read with interest the case report by Radwi and Farsi of a 69-year-old man with acquired
hemophilia A (AHA) following vaccination with the Pfizer-BioNTech SARS CoV-2 mRNA …

Abstract The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the
status of AHA in Spain. One hundred and fifty-four patients were included and …

Emicizumab is currently approved to prevent bleeding in patients with congenital hemophilia
A with or without neutralizing antibodies (inhibitors) against factor VIII (FVIII). Here, we …

Acquired hemophilia A (AHA) is a severe auto‐immune bleeding disorder. Treatment of AHA
is burdensome and optimal management is still unresolved. Therefore a retrospective …

Acquired hemophilia A is an antibody-mediated coagulopathy most often associated with
pregnancy, autoimmunity, malignancy, drugs, or infection. 1 While coagulopathy, generally …

Abstract Background About 1%–5% of acquired haemophilia A cases affect mothers in the
postpartum setting. Aims This study delineates the characteristics of this disease, specific to …

Acquired hemophilia A (AHA) is a rare autoimmune disorder resulting from the formation of
neutralizing antibodies against coagulation factor VIII (FVIII). 1, 2 It is characterized by a …